Current status of antibody therapy in ALL. - Wikidata - wikimedia - TriplyDB

Current status of antibody therapy in ALL.

Current status of antibody therapy in ALL.

http://www.wikidata.org/entity/Q38266338

about

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models.Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems.Muramyl dipeptide and anti-CD10 monoclonal antibody immunoconjugate enhances anti-leukemia immunity of T lymphocytes.Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.

P2860

Q26764903-96B9935B-AAA7-4172-9F2B-71E404BD385A Q26769884-F82D2B92-2863-4A80-B8A0-0C4B940509D4 Q28078210-AD86D6D7-0EDA-4737-AC4B-906FC1761400 Q30275229-EFA8488B-B0EE-4F04-8B64-1BA8E5AC1E99 Q35799427-C55E61D8-102B-408E-8B8C-DA6B63136321 Q37517482-96C48692-B86B-49A3-8D33-C45919173884 Q37696104-B2BD1F9C-CD5B-457E-81F0-5DE62F729C4A Q38757530-0B9BAAD2-8EC3-4D69-82D2-4F9B7E79130D Q39680289-FF5CB3B7-187D-4DCB-9F75-A6A44AF25678 Q50537925-3BA8B84F-C030-4EF5-96EF-C4FDEC876944

P2860

Current status of antibody therapy in ALL.

http://www.wikidata.org/entity/Q38266338

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Current status of antibody therapy in ALL.

@en

type

label

Current status of antibody therapy in ALL.

@en

prefLabel

Current status of antibody therapy in ALL.

@en

P1433

Q38266338-53757833-9F07-4E61-886E-22429CC1E9AC

P1476

Q38266338-8B047125-DBE7-4446-ABD2-556FA6BD2AFD

P2093

Q38266338-73A02E64-8C10-4495-AC55-6DCC5E7F3B11

Q38266338-924820B3-BC44-4B62-A140-151E53DB47A6

P2860

Q38266338-01313CB8-F835-4392-A8FC-EB9AA991A75B

Q38266338-0547D412-2BC9-4030-8E1F-61F199281D98

Q38266338-0D3C5867-EF37-4CA2-978F-64C010DA64F5

Q38266338-16720F04-7A89-427B-BFFF-627B673A6BE8

Q38266338-179C10DC-549F-4C60-9151-11D3D42FBAFA

Q38266338-1A84C8AC-2156-4C9C-98BC-013219DFC65A

Q38266338-2324C3A0-94DB-48CA-9D68-7F101ADA2EDD

Q38266338-37DE1BAF-1461-4E88-923F-27EB64B5BF9D

Q38266338-3E1D7635-304E-4EFD-A665-59690C140920

Q38266338-40AD2385-2D14-4717-8328-8FD3FD11F5D8

P304

Q38266338-E6B74C80-006A-4E07-AF98-3C6DC68FC01E

P31

Q38266338-FDC80078-E29B-41AE-B1BA-D89C03512BD4

P356

Q38266338-B6E9BB63-192D-4039-BAFD-B166D7D818FB

P407

Q38266338-99493076-3EA0-4D03-A8A2-BA304B48A9AA

P433

Q38266338-FA4A00A1-78BC-43FC-8628-CCBEEDD47E2D

P478

Q38266338-C54E5E15-8FD0-460F-96BA-1FFBE15A9FB5

P577

Q38266338-C6D786D8-5061-4813-9FBE-58497AB30236

P698

Q38266338-7D6F7D5B-83C1-4819-93BB-332240266D35

P356

P1433

British Journal of Haematology

P1476

Current status of antibody therapy in ALL.

@en

P2093

Anjali Advani

http://www.w3.org/2001/XMLSchema#string

Jing Ai

http://www.w3.org/2001/XMLSchema#string

P2860

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

P304

471-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13205

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25382151

http://www.w3.org/2001/XMLSchema#string